DENVER, CO, July 26, 2005, GlobeImmune, Inc., a biopharmaceutical company that discovers, develops and manufactures immunotherapeutic products known as Tarmogens™ to treat cancer and infectious disease, today announced that it has initiated a Phase 1b study of GI-5005, a Tarmogen … Continue reading
GlobeImmune Initiates Phase 1b Study of GI-5005 for Chronic Hepatitis C Infection
July 26, 2005